April 28, 2021:

Cellanyx Publishes Paper on MVL/AI driven Test to Predict

Prostate Cancer Tumor Aggressiveness in Reviews in Urology journal.

> Link to Article

December 19, 2018:

Cellanyx Publishes Results of Clinical Proof-of-Concept Study in the Urology.

> Link to Article

October 8, 2018:

Cellanyx Publishes Results of Clinical Validation Study in Nature Biomedical Engineering.

> Link to Article

September 12, 2017:

Cellanyx wins 1st place poster award at the 2nd International Prostate Cancer Symposium, held at Mt. Sinai Hospital.

> Link to Poster

June 15, 2017:

Cellanyx SAB Members Author Publication in Nature Precision Oncology

> Link to Article

June 1, 2017:

Chander AC, Manak MS, Varsanik JS, Hogan BJ, Mouraviev V, Zappala SM, Sant GR, Albala DM (2017) “Rapid and Short Term ECM Mediated In Vitro Culturing of Tumor and Nontumor Human Primary Prostate Cells” Urology

> Link to Paper

> Pubmed Link

September 28, 2016:

Cellanyx Diagnostics’ Live Tumor Cell Phenotypic Risk Stratification Test Data from ‘Normal’ Tissue Samples Recognized at AdMeTech Foundation’s First Global Summit on Precision Diagnosis for Prostate Cancer

Abstract: Analytical Validation of a Live-Cell Phenotypic Biomarker – Based Diagnostic Assay for the Prediction of Adverse Pathology in Prostate Cancer from Field Biopsy Cores.

Second Place Poster Award

Presented at AdMeTech Foundation’s First Global Summit on Precision Diagnosis for Prostate Cancer, 2016.

May 11, 2016:

Cellanyx Demonstrates Clinical Validation of a Novel Live-Cell Phenotypic Biomarker-based Diagnostic Assay for Prostate Cancer.

Abstract: Clinical Validation of a live-cell phenotypic biomarker – based diagnostic assay for the prediction of adverse pathology in Prostate Cancer.

Best Poster Award, 2016 American Urological Association, Prostate Cancer Markers II Moderated Poster Session

Presented at AUA, 2016.

January 20, 2016:

Abstract: A Live Cell Microfluidics Device Utilizing Phenotypic Biomarkers for Prostate Cancer.

Presented at IPCU, 2016.

January 7, 2016:

Cellanyx Presents Latest Clinical Data in Poster Presentation at ASCO – GU Symposium, 2016

Abstract: A Live Cell Microfluidics Device Utilizing Phenotypic Biomarkers for Prostate Cancer.

Presented at ASCO-GU, 2016.

December 7, 2015:

Cellanyx Presents Latest Clinical Data in Poster Presentation at the SUO(Society for Urologic Oncology) Winter Meeting

October 30, 2015:

Abstract: A novel live cell microfluidic diagnostic using phenotypic biomarkers with objective algorithmic analysis for

genitourinary cancer risk stratification.

BJUI Abstract presented at CURA Conference, 2015.

May 15, 2015:

Cellanyx Presents Latest Clinical Data in Poster Presentation at the Annual AUA Meeting

Abstract: A Novel Live Cell Microfluidic Diagnostic Using Phenotypic Biomarkers With Objective Algorithmic Analysis for Prostate Cancer Risk Stratification.

Presented at AUA, 2015.

April 22, 2015:

Cellanyx Presents Phenotypic Test Data For Prostate Cancer Risk Stratification at the AACR Annual Meeting

Abstract: A Novel Live Cell Diagnostic Platform Measuring Phenotypic Biomarkers Using Objective Algorithmic Analysis Enables Further Risk Stratification For Intermediate-Risk Prostate Cancer Patients.

Presented at AACR, 2015.

February 24, 2015:

Novel Live Tumor Cell Diagnostic Test Utilizing Biophysical and Molecular Biomarkers to Assess Local, Advanced, and Metastatic Prostate Cancer

Presented at ASCO Genitourinary Cancers Symposium, 2015.